Pharmacist Digest

As Lilly and BMS invest in manufacturing, demand for drugs still outweighs supply

PharmaVoice

APRIL 25, 2024

From popular weight loss drugs to lifesaving cancer therapies, recent pharma deals show the industry is doubling down on manufacturing capacity to meet demand.

AbbVie and Regenxbio’s ‘multibillion-dollar opportunity’ in vision loss gene therapy

PharmaVoice

APRIL 24, 2024

After a successful mid-stage study, the companies aim to upend traditional wet AMD treatments with a one-time gene therapy.

Inside J&J’s strategy to de-gender clinical trials

PharmaVoice

APRIL 23, 2024

Mark Wildgust, vice president of global medical affairs for J&J's oncology division, shares strategies for making clinical trials gender- and trans-inclusive.

WuXi partnerships at risk as lawmakers target Chinese ties to biopharma

PharmaVoice

APRIL 22, 2024

Why the legislation could throw a wrench into the supply chain for advanced therapies and how the industry has responded.

Vistagen’s on-demand nasal spray could provide a novel option for social anxiety

PharmaVoice

APRIL 22, 2024

The fast-acting medication is one of a few new approaches being tested for the crippling condition.

Behind the ‘encouraging’ new results for Amylyx’s beleaguered drug

PharmaVoice

APRIL 19, 2024

Where Amylyx ultimately failed in ALS, it could prevail in a rare disease. The doctor leading this research explains why.

Roivant spinoff tackles growing complexity of clinical trials

PharmaVoice

APRIL 18, 2024

As precision medicine booms, all trials are starting to look like rare disease trials, the company said.

3 big patent expirations in 2024 and how companies are pivoting

PharmaVoice

APRIL 17, 2024

As the cliffs approach, pharma companies are tackling the sales hit with diverging strategies.

Ukraine was pharma’s ‘darling’ of clinical trials. As war drags on, will the industry come back?

PharmaVoice

APRIL 16, 2024

New clinical trial starts are picking back up, but are still far below their bustling pre-war level.

Orchard sets out to sell world’s priciest gene therapy

PharmaVoice

MARCH 20, 2024

Orchard is counting on the long-term data it’s accrued to convince insurers to cover Lenmeldy’s $4.25 million list price, the highest of any genetic medicine to come to market.

An ocean of answers in a single cell — how proteomics can lead to better drugs

PharmaVoice

MARCH 21, 2024

New tools that allow researchers to separate single cells can help map the complex web of proteins that lead to disease, providing new targets for biopharma.

With historic MASH approval, Madrigal preps for launch and a public offering

PharmaVoice

MARCH 20, 2024

After snagging the first approval for MASH, Madrigal Pharmaceuticals’s drug is primed to become a blockbuster.

After Amylyx drug failure, what’s next for ALS?

PharmaVoice

MARCH 15, 2024

The company’s combo treatment Relyvrio was approved in 2022, but after failing a phase 3 trial, may be pulled from the market.

Former U.S. patent head on why federal march-in rights for drugs would be a ‘devastating’ mistake

PharmaVoice

MARCH 14, 2024

A Biden administration proposal to seize patents for drugs deemed too pricey would have a ripple effect that cuts into the heart of innovation, says former U.S. PTO head Andrei Iancu.

These biotech hotspots are ripe for IPOs

PharmaVoice

MARCH 13, 2024

Biotech IPOs are off to the races in 2024, and investors are betting on horses that are derisked in targeted areas.

The silver lining around Lilly’s Alzheimer’s delay could be a future with better drugs

PharmaVoice

MARCH 12, 2024

Although a regulatory delay for Eli Lilly’s donanemab in Alzheimer’s disease is a competitive setback, researchers have their eye on better drug development as a result.

Drug Development

As colorectal deaths rise among younger people, a screening tool could help pinpoint more patients

PharmaVoice

MARCH 12, 2024

As colorectal deaths rise among younger people, a diagnostic could help pinpoint more patients.

Neurvati touts fresh, ‘synergistic’ investment model in neuroscience R&D

PharmaVoice

MARCH 11, 2024

The Blackstone Life Sciences-backed company plans to focus on later-stage assets to help derisk development.

COVID vaccine giants Moderna and Pfizer employ divergent tactics for the next chapter

PharmaVoice

MARCH 11, 2024

With COVID-19 vaccine sales dying down, Pfizer and Moderna turn to growth in different ways to cement their status as mRNA leaders.

Vaccines

Biotech IPOs heated up to start 2024. Will the surge last?

PharmaVoice

MARCH 5, 2024

Following the sector’s best IPO start in three years, industry insiders shared what they expect to see in the months ahead.

HIV isn’t ‘solved,’ but a doctor who treated some of the first patients hopes to finally deliver a cure

PharmaVoice

MARCH 5, 2024

From San Francisco in the 80s to a gene therapy prospect, Dr. Marcus Conant looks back on his long fight against the virus — and if the industry is close to ending the epidemic.

Ferring’s microbiome and gene therapy firsts take the company beyond reproductive health

PharmaVoice

FEBRUARY 22, 2024

Ferring’s U.S. president Brent Ragans discusses the company’s strategy as it expands into new therapeutic areas and further develops its reproductive pipeline.

AbbVie CEO Richard Gonzalez leaves a divisive Humira legacy and lasting impact on pharma

PharmaVoice

FEBRUARY 22, 2024

Leading AbbVie to become one of the most successful pharmas in the world, Gonzalez also rubbed some critics the wrong way.

4 biotechs to watch in 2024

PharmaVoice

FEBRUARY 21, 2024

A splashy IPO, first-in-class treatments and upcoming approval dates are a few reasons we’ve got our eyes on these biotechs this year.

Behind the breakthrough cancer therapy that just won a historic FDA nod

PharmaVoice

FEBRUARY 21, 2024

The first-of-its-kind TIL therapy for solid tumors developed by Iovance Biotherapeutics won FDA approval last week.

These 4 drugs had tons of promise — and they flopped. What happened?

PharmaVoice

FEBRUARY 13, 2024

No amount of excitement can prevent failures stemming from safety, efficacy, cost and other speed bumps along the way.

3 questions hanging over the Novo-Catalent deal

PharmaVoice

FEBRUARY 13, 2024

As backlash builds for the recently announced matchup, critical questions remain over its impact.

A new (old) mind-opening tool in the fight against Alzheimer’s disease

PharmaVoice

FEBRUARY 12, 2024

A new use for an existing ultrasound technology is seeing early success in getting medications past the blood-brain barrier.

FDA inches closer to defining its regulatory role in AI

PharmaVoice

FEBRUARY 12, 2024

Commissioner Dr. Robert Califf signals how the FDA will consider AI in drug development and how the agency may use the emerging technology in the future.

Drug Development

Government hits patent thickets on multiple fronts

PharmaVoice

FEBRUARY 5, 2024

Patent thickets are the latest target in lawmakers' bid to lower drug prices.

Drug Pricing

Vaxxinity is brewing up meds for a spacefaring future

PharmaVoice

FEBRUARY 5, 2024

The biotech’s bone- and muscle-building treatments could someday help humans reach other planets.

Merck keeps deal focus with Keytruda patent cliff on horizon

PharmaVoice

FEBRUARY 1, 2024

The company is open to deals the size of its prior Acceleron and Prometheus buyouts. “We continue to believe we need more,” CEO Rob Davis said.

Novo, Lilly poised to become first trillion-dollar healthcare companies

PharmaVoice

FEBRUARY 2, 2024

Explosive demand for weight loss drugs has propelled both companies to new heights. Here’s a look at the staggering growth, by the numbers.

‘1 plus 1 equals 3’ — the co-CEO model in pharma

PharmaVoice

JANUARY 26, 2024

Amylyx Pharmaceuticals’ co-founders and co-CEOs Josh Cohen and Justin Klee explain their approach to dual leadership and why it can be a good fit in life sciences.

The biggest questions hanging over pharma in 2024

PharmaVoice

JANUARY 25, 2024

Key trends on the horizon in the life sciences this year.

King’s prostate surgery puts spotlight on men’s health — and new cancer treatments on the way

PharmaVoice

JANUARY 25, 2024

The publicly announced procedure has highlighted one of the most prevalent and deadly cancers among men, and the treatments being developed to combat it.

J&J’s 2024 strategy will focus on newer meds to offset Stelara’s patent cliff

PharmaVoice

JANUARY 24, 2024

Executives on the healthcare giant’s full-year earnings call highlighted a strong cash position and incremental dealmaking as a way to get past incoming competition.

Breast cancer tops list of most studied diseases

PharmaVoice

JANUARY 24, 2024

The most studied diseases last year included three types of cancer as research into COVID-19 fell sharply in the post-pandemic era.

An enduring COVID mystery: Why some do fine and others die

PharmaVoice

JANUARY 17, 2024

The infectious disease market could be shifting toward a future not only focused on the microbe, but on the unique genetic attributes of the host.

FDA chief says agency can’t manage health tech alone

PharmaVoice

JANUARY 16, 2024

FDA Commissioner Dr. Robert Califf recently spoke about the future of AI and machine learning and the need for constant vigilance to improve healthcare systems.

Pharma takes a gut check of microbiome drugs

PharmaVoice

JANUARY 16, 2024

On the heels of two FDA approvals for microbiome-based therapies, interest in the space is gaining steam.

How J&J is tackling a ‘secondary pandemic’ in the Black community

PharmaVoice

JANUARY 8, 2024

J&J is leading a grassroots effort to improve mental health access and care.

Regulatory twists and turns are coming for biopharma in 2024

PharmaVoice

JANUARY 8, 2024

New FDA requirements and the IRA will create complexity in the coming year. Here’s how the industry can navigate the changes.

In the post-pandemic era, three players still dominate the infectious disease market

PharmaVoice

JANUARY 5, 2024

Although three companies dominate the space, emerging infectious disease focus areas and a handful of other key players are augmenting the market.

PharmaVoice

As Lilly and BMS invest in manufacturing, demand for drugs still outweighs supply

AbbVie and Regenxbio’s ‘multibillion-dollar opportunity’ in vision loss gene therapy

Trending Sources

Inside J&J’s strategy to de-gender clinical trials

WuXi partnerships at risk as lawmakers target Chinese ties to biopharma

Vistagen’s on-demand nasal spray could provide a novel option for social anxiety

Behind the ‘encouraging’ new results for Amylyx’s beleaguered drug

Roivant spinoff tackles growing complexity of clinical trials

3 big patent expirations in 2024 and how companies are pivoting

Ukraine was pharma’s ‘darling’ of clinical trials. As war drags on, will the industry come back?

Orchard sets out to sell world’s priciest gene therapy

An ocean of answers in a single cell — how proteomics can lead to better drugs

With historic MASH approval, Madrigal preps for launch and a public offering

After Amylyx drug failure, what’s next for ALS?

Former U.S. patent head on why federal march-in rights for drugs would be a ‘devastating’ mistake

These biotech hotspots are ripe for IPOs

The silver lining around Lilly’s Alzheimer’s delay could be a future with better drugs

As colorectal deaths rise among younger people, a screening tool could help pinpoint more patients

Neurvati touts fresh, ‘synergistic’ investment model in neuroscience R&D

COVID vaccine giants Moderna and Pfizer employ divergent tactics for the next chapter

Biotech IPOs heated up to start 2024. Will the surge last?

HIV isn’t ‘solved,’ but a doctor who treated some of the first patients hopes to finally deliver a cure

Ferring’s microbiome and gene therapy firsts take the company beyond reproductive health

AbbVie CEO Richard Gonzalez leaves a divisive Humira legacy and lasting impact on pharma

4 biotechs to watch in 2024

Behind the breakthrough cancer therapy that just won a historic FDA nod

These 4 drugs had tons of promise — and they flopped. What happened?

3 questions hanging over the Novo-Catalent deal

A new (old) mind-opening tool in the fight against Alzheimer’s disease

FDA inches closer to defining its regulatory role in AI

Government hits patent thickets on multiple fronts

Vaxxinity is brewing up meds for a spacefaring future

Merck keeps deal focus with Keytruda patent cliff on horizon

Novo, Lilly poised to become first trillion-dollar healthcare companies

‘1 plus 1 equals 3’ — the co-CEO model in pharma

The biggest questions hanging over pharma in 2024

King’s prostate surgery puts spotlight on men’s health — and new cancer treatments on the way

J&J’s 2024 strategy will focus on newer meds to offset Stelara’s patent cliff

Breast cancer tops list of most studied diseases

An enduring COVID mystery: Why some do fine and others die

FDA chief says agency can’t manage health tech alone

Pharma takes a gut check of microbiome drugs

How J&J is tackling a ‘secondary pandemic’ in the Black community

Regulatory twists and turns are coming for biopharma in 2024

In the post-pandemic era, three players still dominate the infectious disease market

Stay Connected